Published on 08/06/2026

Essential ADR Reporting Template for Indian Pharmaceutical Firms

Introduction to ADR Reporting in India

Adverse Drug Reactions (ADRs) are critical indicators of drug safety and efficacy. For Indian pharmaceutical companies, adhering to the guidelines set forth in Revised Schedule M is essential for compliance with the Central Drugs Standard Control Organization (CDSCO). This article provides a comprehensive checklist and a sample ADR reporting form to assist in the effective management of pharmacovigilance (PV) responsibilities.

Importance of ADR Reporting

Timely and accurate ADR reporting is vital for ensuring patient safety and maintaining regulatory compliance. It helps in identifying potential risks associated with drugs and facilitates necessary actions to mitigate these risks. Moreover, effective ADR reporting can enhance a company’s reputation and trustworthiness in the market.

Components of an ADR Reporting Form

A well-structured ADR reporting form should include the following key components:

• Patient Information: Name, age, gender, and medical history.
• Drug Information: Name of the drug, dosage, route of administration, and duration of therapy.
• Adverse Reaction Details: Description of the reaction, onset date, severity, and outcome.
• Reporter Information: Name, designation, and contact details of the reporter.
• Additional Notes: Any relevant information that may aid in the assessment of the ADR.

Sample ADR Reporting Form

Below is a sample template that Indian pharmaceutical companies can utilize for ADR reporting:

Field	Details
Patient Name	[Insert Name]
Age	[Insert Age]
Gender	[Insert Gender]
Drug Name	[Insert Drug Name]
Dosage	[Insert Dosage]
Adverse Reaction	[Insert Description]
Date of Onset	[Insert Date]
Severity	[Insert Severity]
Outcome	[Insert Outcome]
Reporter Name	[Insert Reporter Name]
Contact Details	[Insert Contact]

Integrating PV SOPs with Quality Assurance

To ensure compliance with pharmacovigilance requirements, it is crucial to integrate PV Standard Operating Procedures (SOPs) with the overall Quality Assurance (QA) framework. This integration helps in:

• Establishing clear protocols for ADR reporting and management.
• Facilitating training and awareness among staff regarding PV practices.
• Ensuring continuous monitoring and improvement of pharmacovigilance activities.

Documentation and CAPA in Pharmacovigilance

Proper documentation is a cornerstone of effective pharmacovigilance. It is essential to maintain records of all ADR reports, investigations, and actions taken. Additionally, implementing Corrective and Preventive Actions (CAPA) is vital to address any discrepancies or issues identified during the reporting process. Steps to ensure effective CAPA include:

• Identifying root causes of ADRs.
• Implementing corrective measures to prevent recurrence.
• Monitoring the effectiveness of CAPA actions.

Preparing for CDSCO Inspections

CDSCO inspections can be rigorous, and being well-prepared is essential for compliance. Key preparation strategies include:

• Regularly reviewing and updating ADR reporting forms and SOPs.
• Conducting internal audits to assess compliance with pharmacovigilance requirements.
• Training staff on the importance of accurate and timely ADR reporting.

FAQs

1. What is the purpose of ADR reporting?

The purpose of ADR reporting is to monitor the safety of pharmaceutical products and ensure patient safety by identifying potential risks associated with drug use.

2. Who is responsible for ADR reporting in a pharmaceutical company?

The pharmacovigilance team, along with healthcare professionals and other relevant staff, is responsible for ADR reporting within a pharmaceutical company.

3. How often should ADR reports be submitted to CDSCO?

ADRs must be reported to CDSCO within specified timelines, typically within 14 days for serious adverse events and within 30 days for non-serious events.

4. What are the consequences of failing to report ADRs?

Failure to report ADRs can lead to regulatory penalties, loss of market authorization, and damage to the company’s reputation.

5. How can companies ensure compliance with pharmacovigilance regulations?

Companies can ensure compliance by implementing robust PV SOPs, maintaining accurate documentation, conducting regular training, and preparing thoroughly for inspections.

Related Resources

For more information on pharmacovigilance compliance and best practices, visit our Pillar Page on Schedule M Pharmacovigilance Compliance.

{“@context”:”https://schema.org”,”@type”:”Article”,”headline”:”Sample ADR Reporting Form for Indian Pharma Companies”,”articleSection”:”PV SOPs Templates & Checklists”,”keywords”:”schedule m,pv compliance,cdsco,pharmacovigilance,drug safety,india,gmp,pv inspections”}